Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:AVIR NASDAQ:BGM NASDAQ:NAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$7.92+4.3%$8.05$5.20▼$10.67$1.07B1.161.38 million shs460,619 shsAVIRAtea Pharmaceuticals$3.74+2.0%$3.12$2.46▼$4.15$319.64M0.25322,714 shs87,176 shsBGMBGM Group$9.99+0.6%$12.44$5.26▼$17.17$970.74M1.2934,065 shs21,469 shsNAGENiagen Bioscience$12.14+1.4%$11.58$2.52▼$14.69$956.27M2.14879,392 shs287,580 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.61%+1.47%-7.33%-0.26%+34.81%AVIRAtea Pharmaceuticals+0.27%+1.39%+14.78%+33.21%+11.28%BGMBGM Group-0.70%-3.78%-24.08%-8.82%+992,999,900.00%NAGENiagen Bioscience-3.78%-6.56%-7.57%+98.18%+376.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.5668 of 5 stars3.51.00.00.01.90.81.9AVIRAtea Pharmaceuticals2.3203 of 5 stars3.32.00.00.00.62.51.3BGMBGM GroupN/AN/AN/AN/AN/AN/AN/AN/ANAGENiagen Bioscience1.2976 of 5 stars3.50.00.00.01.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5045.20% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0060.64% UpsideBGMBGM Group 0.00N/AN/AN/ANAGENiagen Bioscience 3.00Buy$19.5060.63% UpsideCurrent Analyst Ratings BreakdownLatest AVIR, AUPH, BGM, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.33$0.33 per share24.22$2.68 per share2.96AVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ABGMBGM Group$25.10M38.67N/AN/A$7.34 per share1.36NAGENiagen Bioscience$107.93M8.86$0.06 per share210.32$0.60 per share20.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2828.2314.14N/A16.11%14.27%9.93%7/30/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)BGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ANAGENiagen Bioscience$8.55M$0.1771.41∞N/A13.07%19.06%12.20%N/ALatest AVIR, AUPH, BGM, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025AVIRAtea Pharmaceuticals-$0.44N/AN/AN/AN/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ABGMBGM GroupN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26AVIRAtea PharmaceuticalsN/A19.9419.94BGMBGM GroupN/AN/AN/ANAGENiagen BioscienceN/A3.663.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%AVIRAtea Pharmaceuticals86.67%BGMBGM GroupN/ANAGENiagen Bioscience15.41%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%AVIRAtea Pharmaceuticals18.10%BGMBGM Group58.66%NAGENiagen Bioscience9.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableBGMBGM Group29897.22 million40.19 millionN/ANAGENiagen Bioscience12078.77 million71.37 millionN/AAVIR, AUPH, BGM, and NAGE HeadlinesRecent News About These CompaniesNiagen Bioscience stock rises on exclusive Parkinson’s treatment licenseJuly 9 at 2:48 AM | in.investing.comNiagen Bioscience Shares Climb Following Exclusive License for Parkinson’s TherapyJuly 9 at 2:48 AM | msn.comNiagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, NorwayJuly 8 at 8:32 AM | businesswire.comNAGE - Niagen Bioscience Inc Executives - MorningstarJuly 1, 2025 | morningstar.comMNiagen Bioscience (NASDAQ:NAGE) Stock Price Down 9.5% - Here's What HappenedJuly 1, 2025 | marketbeat.comEarnings Forecast & History for Niagen Bioscience Inc (NAGE) | Price ReactionsJuly 1, 2025 | investing.comNiagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year High - What's Next?June 30, 2025 | marketbeat.com2NAGE : Breaking Update: Wendy Tak Wing YU Engages In Options Exercise At Niagen...June 27, 2025 | benzinga.com1NAGE : Engaging In Insider Activity, Kristin Patrick At Niagen Bioscience Exercises...June 27, 2025 | benzinga.comMajor Update: Frank Jaksch Jr At Niagen Bioscience Exercises Options, Realizing $0June 26, 2025 | benzinga.comOptions Exercise Update At Niagen Bioscience: Ann Cohen Engages, Resulting In $0June 26, 2025 | benzinga.comSteven Rubin At Niagen Bioscience Exercises Options Worth $0June 26, 2025 | benzinga.comNiagen Bioscience, Inc. (NAGE) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNiagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic TrendsJune 24, 2025 | seekingalpha.comEven though Niagen Bioscience (NASDAQ:NAGE) has lost US$55m market cap in last 7 days, shareholders are still up 623% over 3 yearsJune 23, 2025 | finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Raised to Strong-Buy at Wall Street ZenJune 22, 2025 | marketbeat.comNiagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | finanznachrichten.deNiagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | businesswire.comNiagen Bioscience (NASDAQ:NAGE) Shares Down 2.4% - Should You Sell?June 18, 2025 | marketbeat.comNiagen Bioscience (NASDAQ:NAGE) Downgraded to Buy Rating by Wall Street ZenJune 14, 2025 | marketbeat.comChromaDex Corp (OCD1.DU)June 11, 2025 | nz.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVIR, AUPH, BGM, and NAGE Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$7.92 +0.33 (+4.35%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Atea Pharmaceuticals NASDAQ:AVIR$3.74 +0.08 (+2.05%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.BGM Group NASDAQ:BGM$9.98 +0.06 (+0.55%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Niagen Bioscience NASDAQ:NAGE$12.14 +0.17 (+1.42%) As of 11:23 AM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound Rises as Short Sellers Exit and AI Demand Grows Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
